Evidence map›Paper›PMID 28489911›Full record

ArticlePloS one2017

Human β-defensin-2 production upon viral and bacterial co-infection is attenuated in COPD.

Jason W Arnason, James C Murphy, Cora Kooi, Shahina Wiehler, Suzanne L Traves, Christopher Shelfoon, Barbara Maciejewski, Curtis J Dumonceaux, W Shawn Lewenza, David Proud and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Rhinovirus and COPD airway epithelium.Pulmonary and critical care medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jason W ArnasonDepartment of Medicine, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
James C MurphyDepartment of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Cora KooiDepartment of Medicine, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Shahina WiehlerDepartment of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Suzanne L TravesDepartment of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Christopher ShelfoonDepartment of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Barbara MaciejewskiDepartment of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Curtis J DumonceauxDepartment of Medicine, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
W Shawn LewenzaDepartment of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
David ProudDepartment of Physiology & Pharmacology, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Richard LeighDepartment of Medicine, Snyder Institute for Chronic Diseases, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
University of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral-bacterial co-infections are associated with severe exacerbations of COPD. Epithelial antimicrobial peptides, including human β-defensin-2 (HBD-2), are integral to innate host defenses. In this study, we examined how co-infection of airway epithelial cells with rhinovirus and Pseudomonas aeruginosa modulates HBD-2 expression, and whether these responses are attenuated by cigarette smoke and in epithelial cells obtained by bronchial brushings from smokers with normal lung function or from COPD patients. When human airway epithelial cells from normal lungs were infected with rhinovirus, Pseudomonas aeruginosa, or the combination, co-infection with rhinovirus and bacteria resulted in synergistic induction of HBD-2 (p<0.05). The combination of virus and flagellin replicated this synergistic increase (p<0.05), and synergy was not seen using a flagella-deficient mutant Pseudomonas (p<0.05). The effects of Pseudomonas aeruginosa were mediated via interactions of flagellin with TLR5. The effects of HRV-16 depended upon viral replication but did not appear to be mediated via the intracellular RNA helicases, retinoic acid-inducible gene-I or melanoma differentiation-associated gene-5. Cigarette smoke extract significantly decreased HBD-2 production in response to co-infection. Attenuated production was also observed following co-infection of cells obtained from healthy smokers or COPD patients compared to healthy controls (p<0.05). We conclude that co-exposure to HRV-16 and Pseudomonas aeruginosa induces synergistic production of HBD-2 from epithelial cells and that this synergistic induction of HBD-2 is reduced in COPD patients. This may contribute to the more severe exacerbations these patients experience in response to viral-bacterial co-infections.

Indexed as

Bacterial Infectionsbeta-DefensinsCells, CulturedGene Knockdown TechniquesHumansPulmonary Disease, Chronic ObstructiveSmokingToll-Like Receptor 5Virus Diseasesbeta-DefensinsTLR5 protein, humanToll-Like Receptor 5

Identifiers

PMID28489911
PMCPMC5425185
OpenAlexW2613590306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.